Barbara Yanni - 10 May 2024 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Reporting relationship
Director
Issuer ticker
VCNX
Reported as of
10 May 2024
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 May 2024, 16:33:55 UTC
Prior SEC filing
20 Jun 2023
Next SEC filing
14 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Maurice Zauderer, Attorney-in-Fact for Barbara Yanni

Key filing fact

Barbara Yanni filed Form 4 for VACCINEX, INC. (VCNX) on 14 May 2024.

Key facts

  • This page summarizes Barbara Yanni's Form 4 filing for VACCINEX, INC. (VCNX).
  • 1 reported transaction and 7 derivative rows are listed below.
  • Accepted by SEC: 14 May 2024, 16:33.

Change

  • Previous filing in this sequence was filed on 20 Jun 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VCNX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+10,108
Change %
Price
$0.000000
Shares after
10,108
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,108
Exercise price
$5.75
Footnotes
F7
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
30
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30
Exercise price
$2856.00
Footnotes
F1
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
36
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
36
Exercise price
$1633.80
Footnotes
F2
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
74
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
74
Exercise price
$829.50
Footnotes
F3
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
136
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
136
Exercise price
$451.50
Footnotes
F4
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
253
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
253
Exercise price
$235.20
Footnotes
F5
VCNX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
684
Date
10 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
684
Exercise price
$86.10
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Exercisable in full as of the date of this report.

Footnote F2

This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.

Footnote F3

This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.

Footnote F4

This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.

Footnote F5

This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.

Footnote F6

This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.

Footnote F7

This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC remarks

All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .